FDA gives emergency use approval for Covid-19 antibody drug developed by Vir Biotechnology, GlaxoSmithKline
Excerpt from the Article:
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
The antibody drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy, the health regulator said on Wednesday.
Sotrovimab belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies that the body generates to fight off infection.
Click the button below to read the entire Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?